FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2 Disease, Form of Batten Disease

Potential First Treatment for Fatal, Rare, Brain Disease in Children

FDA Grants Priority Review Status and Breakthrough Therapy Designation

PDUFA Action Date is January 27, 2017

MAA Submitted to European Regulatory Authorities

SAN RAFAEL, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the submission of a Biologics License Application (BLA) for cerliponase alfa, an investigational therapy to treat children with CLN2 disease, a form of Batten disease. The Prescription Drug User Fee Act (PDUFA) goal date for a decision is January 27, 2017. BioMarin also has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for cerliponase alfa, and it is undergoing validation at the Agency.

The FDA granted cerliponase alfa Priority Review status, which is designated to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. Cerliponase alfa was previously granted Orphan Drug Designation and Breakthrough Therapy Designation by the FDA. 

The company also announced that the preliminary approved brand name for cerliponase alfa is Brineura™.

“CLN2 disease is a rapidly progressing, fatal neurodegenerative disease with no approved treatments. The FDA recognized the potential of cerliponase alfa to help address this devastating condition, and we look forward to working closely with the Agency over the coming months," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "We thank the community for its continued support, as well as the patients and families who dedicated their time to the clinical development of cerliponase alfa.”

"This is an historic milestone for the Batten disease community. For the first time since it was originally described more than a century ago, there is a potential treatment for our children with CLN2 disease,” said Margie Frazier, PhD, Executive Director of the Batten Disease Support and Research Association. “We appreciate BioMarin’s continued commitment to pursue a therapy for this devastating disease and to advancing it quickly through the development process."

Children with CLN2 disease typically begin to present symptoms between the ages of two and four, with the majority of affected children losing their ability to walk and talk by approximately six years of age. Initial symptoms can include language delay and seizures, followed by movement disorders, motor deterioration, dementia and blindness. During the later stages of the disease, feeding and tending to everyday needs become very difficult, and death often occurs between 8 and 12 years of age.

Early Access Program

BioMarin is planning to implement an early access program to provide access to treatment for additional CLN2 patients prior to obtaining marketing approval. The program will be limited in scope and number of participants and will be conducted under a protocol. BioMarin expects that the program will be conducted initially at centers that have participated in the cerliponase alfa study. Those sites have experience administering this drug directly to the brain and would ensure continued patient monitoring. 

The timing of the start of the program is on track, and the initial site is expected to be open during Q3 2016. The exact timing will vary by country of the sites participating. The overall scope and details of this program are still being determined. BioMarin must adhere to specific legal procedures for each country and has begun these preparations with the goal of being ready to dose patients in Q3 2016.

About Cerliponase Alfa

Cerliponase alfa is a recombinant form of human tripeptidyl peptidase 1 (TPP1), the enzyme deficient in patients with CLN2 disease. It is an enzyme replacement therapy designed to restore TPP1 enzyme activity and break down the storage materials that cause CLN2 disease. In order to reach the cells of the brain and central nervous system, the treatment is delivered directly to the fluid surrounding the brain (cerebrospinal fluid) by intracerebroventricular (ICV) infusion, an established technique for delivering drugs to the brain.

For additional information regarding the investigational product cerliponase alfa, please contact BioMarin Medical Information at  medinfo@bmrn.com .

About CLN2 Disease

CLN2 disease is caused by mutations in the TPP1/CLN2 gene, resulting in deficient activity of the enzyme TPP1. In the absence of TPP1, lysosomal storage materials normally metabolized by this enzyme accumulate in many organs, particularly in the brain and retina. Buildup of these storage materials in the cells of the nervous system contribute to progressive and relentless neurodegeneration, which manifests as loss of cognitive, motor and visual functions.

There is no approved treatment that can prevent, stop or reverse CLN2 disease. Symptomatic care to treat disease symptoms, prevent and treat complications, and attempt to preserve quality of life is the only currently available option for patients with this rare disease.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.

For additional information, please visit  www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: BioMarin's development programs for cerliponase alfa generally, and specifically about regulatory filings for commercial approval of the product candidate. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results of current and planned clinical trials of cerliponase alfa; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities; our ability to manufacture sufficient quantities of cerliponase alfa for clinical trials, commercial launch and other preapproval requirements; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2015 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin ® is a registered trademark and Brineura™ is a trademark of BioMarin Pharmaceutical Inc.

 

Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cinmoore's Smart Camera: A Game Changer for Car Security

Updated Category News Views 96

Pioneering Car Security with Cinmoore's Smart Camera Ever left your car in the parking lot, heart pounding, wondering if it's safe while you run errands? Well, Cinmoore might just quell that parking paranoia with their new gizmo, the Smart Parking Camera DC1U. This device isn't just some fancily-packaged disappointment—it promises some serious peace of mind for those...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 94

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 55

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 98

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 86

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 25

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 73

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Legacy of Lovers Unveils Transformative Single Addition

Updated Category News Views 154

Legacy of Lovers Launches New Musical Journey with 'Calm Cool Connection' With an exciting new release, Endless Love embraces the future of music with their single 'Calm Cool Connection'. This dynamic piece captures the essence of personal transformation and encourages listeners to embrace their own journeys. The track stands out, infused with bright melodies and...

Continue Reading
Major Shareholding Update for Park Street A/S Shareholders

Updated Category News Views 162

Significant Shareholding Announcement Park Street A/S is making headlines with its recent announcement regarding major shareholder developments. The company, a key player in its industry, has disclosed essential updates about the share capital and voting rights held by Park Street Asset Management Ltd., a trusted partner in managing its shareholding. Capital Reduction and...

Continue Reading
Alamos Gold's Robust Quarterly Dividend and Strategic Buybacks

Updated Category News Views 150

Quarterly Dividend Announcement by Alamos Gold All figures mentioned are in United States dollars unless specified otherwise. In a recent announcement, Alamos Gold Inc. (TSX:AGI; NYSE:AGI) has revealed a significant update regarding its shareholder value strategies. The Company’s Board of Directors has declared a quarterly dividend of US$0.025 per common share. This...

Continue Reading
AITX Expands Innovative Logistics Solutions with ROAMEO

Updated Category News Views 98

Revolutionizing Logistics with AITX and ROAMEO In an ever-changing world of logistics, AITX’s Robotic Assistance Devices, Inc. (RAD) is stepping up to the plate with new solutions that elevate operational efficiency and security standards. The company has honed its focus on creating tailored solutions for the logistics sector, which is widely acknowledged for its...

Continue Reading
BlackRock's Bold Bet on Bitcoin Amid Microsoft's Hesitation

Updated Category News Views 131

BlackRock's Investment Insights Into Bitcoin Microsoft Corp. (NASDAQ: MSFT) recently made headlines when it decided against exploring Bitcoin as a potential investment. Despite this, its significant shareholder, BlackRock, is making waves with its strong backing for the leading cryptocurrency. Known for its strategic investments, BlackRock's optimism presents a stark...

Continue Reading